James E. Wagner Cultivation Corporation (TSX:JWCA.V,OTCQX:JWCAF) will be adding single origin lot kief and pre-rolls to its medical product shelf, marking the launch of JWC’s first cannabis 2.0 products into the Canadian market.
As quoted in the press release:
The kief and the pre-rolls are prepared using single origin lots of cannabis grown with JWC’s proprietary GrowthSTORM™ aeroponic cultivation platform. JWC is commencing its launch of these two product formats into the Canadian market later today via JWC’s online medical shop, which is accessible through its website www.jwc.ca.
Pre-Rolls: A single origin product, JWC cannabis pre-rolls are evenly milled, machine-rolled, and individually hand-finished in a convenient format.
Kief: A single origin extract product, these sugar-like crystals are known for their fulsome terpene profile, potency, and versatility. Carefully made using freshly harvested cannabis material, this product is recognized as one of the truest representations of the cannabis strain.
Aurora Cannabis Announces Filing of Preliminary Base Shelf Prospectus and Provides Update on Balance Sheet Strength
- Existing At-The-Market (ATM) program now complete
- New Preliminary Base Shelf Prospectus Has Been Filed
- Current Cash Position is Approximately $272 million
NYSE | TSX: ACB
Aurora Cannabis Inc. (the ” Company ” or ” Aurora “) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced it has completed the previously filed At-The-Market (“ATM”) program. Because of this, the Company has filed a new preliminary short form base shelf prospectus (the “Shelf Prospectus”) with securities regulators in each of the provinces of Canada except Quebec and a corresponding shelf registration statement on Form F–10 (the “Registration Statement”) with the United States Securities and Exchange Commission (the “SEC”).
Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) is pleased to announce that its majority owned subsidiary NeonMind Biosciences (“NeonMind”) has completed an initial production run of all four of its Ayurvedic, functional mushroom coffees.
Inaugural runs of the award-winning and new white-label brands will allow the infused beverage expert to move ahead quickly with commercialization plans
Emerging leader in infused cannabis beverages, BevCanna Enterprises Inc. (CSE:BEV) (OTCQB:BVNNF) (FSE:7BC) (“BevCanna” or the “Company”) is pleased to announce that it has successfully completed the R&D and trial production runs of its exclusively licenced award winning line of Keef Beverages and the white-label beverages the Company is producing for State B Beverages.
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“U.S. FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19. The Company has committed to ten clinical sites across Florida, Texas, Nevada, Arizona and California, and it is estimated that over 200 patients will have completed the Study for the interim analysis by the end of December 2020. The interim analysis will determine the better performing Bucillamine dose arm for the remainder of the trial and future complementary studies evaluating it in more severe cases, thus making Bucillamine a potential treatment option.
“We are one of a few life sciences companies evaluating an investigational drug in a Phase 3 clinical trial for COVID-19 and with the rising prevalence of cases throughout the U.S., we are confident that our targets will be achieved to support the potential FDA approval and commercialization of Bucillamine for the treatment of the virus,” said Michael Frank, Revive’s Chief Executive Officer.